← Back to Clinical Trials
Recruiting NCT07052916

NCT07052916 A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07052916
Status Recruiting
Phase
Sponsor Memorial Sloan Kettering Cancer Center
Condition Blood Cancer
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2025-06-27
Primary Completion 2026-12-27

Trial Parameters

Condition Blood Cancer
Sponsor Memorial Sloan Kettering Cancer Center
Study Type INTERVENTIONAL
Phase N/A
Enrollment 60
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2025-06-27
Completion 2026-12-27
Interventions
Music Therapy/MTTherapist-Attention Music Education/TAME Control

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Research has shown that music-based activities may help improve brain functions, such as attention, memory, and executive function. Because of this past research, the researchers are doing this study to find out whether telehealth music therapy is a practical treatment for cognitive difficulties in blood cancer survivors. The researchers will also study whether music therapy and music education help improve cognitive function and other common symptoms such as anxiety, depression, and/or tiredness.

Eligibility Criteria

Inclusion Criteria: * English-proficient, aged 18 or older * Diagnosis of lymphoma, leukemia, or myeloma * Stable oncologic disease or no evidence of disease as indicated in the medical chart or by the oncology team * Score of \<54 on the FACT-Cog PCI subscale * Minimum life expectancy of one year as per clinician assessment * Patient should be able to understand and complete all study assessments on their own. * Eligible patient should be able to understand informed consent and provide signed informed consent in English. Exclusion Criteria: * Less than 3 months since completion of surgery, radiation, induction chemotherapy (for newly diagnosed or relapsed disease), transplantation, or immunotherapy (e.g., CAR T-Cell, bispecific antibodies) * If there is a defined treatment period, the patient must be at least 3 months from treatment completion * If the patient is on continuous therapy, patient must have completed at least 6 months of the therapy * Maintenance therapies are allowed * R

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology